SchizophreniaPhase 4CASPARNCT04940039
A Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
A Phase 4 study testing Risperidone 3 mg, Paliperidone Palmitate 50 mg eq. and Paliperidone Palmitate 75 mg eq. in people with Schizophrenia, run by Janssen-Cilag International NV at 5 sites in Rwanda.
Trial summary
The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings… Read more about this study
- Who is it for?
- Ages 19 to 34 years
- Conditions the study is for
- Schizophrenia
- What is being tested?
- Risperidone 3 mg, Paliperidone Palmitate 50 mg eq. and Paliperidone Palmitate 75 mg eq.
- Type of treatment
- Pill or oral medicine, Injection or infusion
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 93 participants
- Where
- 5 sitesRwanda
- Study dates
- 22 Jul 2021to 16 Apr 2024
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 19 to 34 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Diagnosis of schizophrenia by Mini International Neuropsychiatric Interview (MINI)-Screen / MINI (Module K) that requires treatment initiation or a change in treatment to better address safety, efficacy, or adherence limitations of current treatment
- Eligible for treatment in the Rwandan mental healthcare system
- At least moderately ill as measured by the Clinical Global Impression - Severity of Schizophrenia (CGI-SS) scale for schizophrenia (rating of greater than or equal to [>=] 4). This criterion needs to be re-confirmed at Visit 2
- Has a primary caregiver who is willing to participate in this study (caregiver should be knowledgeable about the participant's condition, provide economic/cost of care information, and is expected to be with the participant for greater than [>] 24 hours each week for the duration of the study)
- A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) during screening
- Able to give consent to participate in a clinical study that includes treatment with risperidone and long-acting injectable (LAI) formulations of paliperidone palmitate. Participants must be willing to receive injections. The participant and the caregiver must sign their own informed consent form (ICF) indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study
Who cannot join
- Has a physical, mental, or legal incapacity that prevents a valid consent or capacity to complete about 12 months of treatment with antipsychotic medication and compliance with this study protocol
- History of organic brain syndromes, comorbid psychiatric and/or physical illnesses, or significant comorbid substance abuse that is likely to interfere with understanding of or compliance with study requirements
- Known allergies, hypersensitivity, or intolerance to risperidone or paliperidone palmitate or its excipients
- Received an investigational intervention including investigational vaccines or used an invasive investigational medical device within 30 days before the planned first dose of study intervention, or is currently enrolled in an investigational study
- Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study intervention
- Poor prior response to risperidone or paliperidone
Trial locations and contacts
5 sites in 1 country.
5 sites in 1 country
Rwanda5 sites
University Teaching Hospital of Butare(CHUB)
Butare, NAP
Kibuye Referral Hospital
Kibuye, POBOX44
CARAES Ndera Neuro-Psychiatric Hospital
Kigali, 423
University Teaching Hospital of Kigali
Kigali, KN4
Rwamagana Provincial Hospital
Rwamagana
About this study
Official title: Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month [PP1M] and 3-month [PP3M] formulations).
- Conditions
- Schizophrenia
- Being tested
- Risperidone 3 mg, Paliperidone Palmitate 50 mg eq., Paliperidone Palmitate 75 mg eq., Paliperidone Palmitate 100 mg eq., Paliperidone Palmitate 150 mg eq.
- Keywords
- Long-acting injectable antipsychotics, Low income countries, schizophrenia
- Medical subject headings
- Schizophrenia
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Risperidone 3 mgDrug
Participants will receive 3 mg oral risperidone tablet once daily for 3 days.
Paliperidone Palmitate 50 mg eq.Drug
Also called R092670
Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks).
Paliperidone Palmitate 75 mg eq.Drug
Also called R092670
Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 100 mg eq.Drug
Also called R092670
Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 150 mg eq.Drug
Also called R092670
Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks.
Paliperidone Palmitate 175 mg eq.Drug
Also called R092670
Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 263 mg eq.Drug
Also called R092670
Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 350 mg eq.Drug
Also called R092670
Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks.
Paliperidone Palmitate 525 mg eq.Drug
Also called R092670
Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks.
| Study group | Role | What they receive |
|---|---|---|
| Paliperidone Palmitate | Experimental | Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their routine clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks. Receives: Drug: Risperidone 3 mg; Drug: Paliperidone Palmitate 50 mg eq.; Drug: Paliperidone Palmitate 75 mg eq.; Drug: Paliperidone Palmitate 100 mg eq.; Drug: Paliperidone Palmitate 150 mg eq.; Drug: Paliperidone Palmitate 175 mg eq.; Drug: Paliperidone Palmitate 263 mg eq.; Drug: Paliperidone Palmitate 350 mg eq.; Drug: Paliperidone Palmitate 525 mg eq. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}])
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Measured: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Secondary outcomes (21)
Mean Change in CGI-SS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Measured: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Mean Change in CGI-SS Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
Measured: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Personal and Social Performance (PSP) Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Measured: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in PSP Scale Scores from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Measured: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in PSP Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The PSP scale assesses the degree of difficulty a participant exhibits over a 7-day period within 4 domains of behavior: a) socially useful activities, b) personal and social relationships, c) self-care, and d) disturbing and aggressive behavior. The impairment of each domain is rated on a 6-point basis, including absent (0), mild (1), moderate (2), marked (3), severe (4), and very severe (5). The higher domain score, therefore, indicates, worse functioning in that area.
Measured: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Measured: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Measured: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The patient satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Measured: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Measured: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in Clinician Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Measured: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The clinician satisfaction rating is a 4-item scale. Two items use a Likert scale with a 6-point range (0 [very dissatisfied] to 5 [very satisfied]) and 2 items are multiple-choice (example, "select all that apply"). Higher score indicates greater satisfaction.
Measured: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Schizophrenia Quality of Life Scale (SQLS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Measured: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in SQLS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Measured: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in SQLS Score from Visit 2 (Week 1) to Visit 6 (Week 25)
The SQLS has 33 items covering topics such as psychosocial feelings and vitality. Response options are never, rarely, sometimes, often, or always. Scoring algorithms yield a 0 to 100 scale, with higher scores indicating lower quality of life.
Measured: Visit 2 (Week 1) to Visit 6 (Week 25)
Number of Participants with Treatment-emergent Adverse Events
An adverse event is any untoward medical occurrence in a clinical study participants administered a medicinal (investigational or non-investigational) product. An adverse event does not necessarily have a causal relationship with the intervention. Treatment-emergent adverse events are adverse events with onset after the initiation of treatment in observation phase and separately for initiation of paliperidone palmitate (PP) in Lead-in phase or that are a consequence of a pre-existing condition that has worsened after each treatment phase starts.
Measured: Up to Week 66
Number of Participants with Abnormalities in Clinical Laboratory Measures
Number of participants with abnormalities in clinical laboratory measures (including serum chemistry, hematology and urinalysis) will be reported.
Measured: Up to Week 66
Number of Participants with Abnormalities in Vital Signs
Number of participants with abnormalities in vital signs (temperature [oral], pulse/heart rate, and blood pressure) will be reported.
Measured: Up to Week 66
Number of Participants with Abnormalities in Electrocardiogram (ECG)
Number of participants with abnormalities in ECG will be reported.
Measured: Up to Week 66
Number of Participants with Abnormalities in Physical Examination
Number of participants with abnormalities in physical examination (including body weight, waist circumference, and height) will be reported.
Measured: Up to Week 66
Number of Participants With Pregnancy Outcome as a Safety Measure
Number of participants with pregnancy outcome will be reported.
Measured: Up to Week 66
Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS) Score
C-SSRS is an approved and standardized scale for the assessment of the severity of suicidality, through clinical interview. The maximum score assigned for each participant will be summarized into one of three categories: no suicidal ideation or behavior (0), suicidal ideation (1-5), suicidal behavior (6-10). Total score ranges from 1 to 10. Higher scores indicate greater severity. Number of participants with suicidal ideation and behavior will be reported.
Measured: Visit 12 (Week 46) to Visit 14 (Week 66 [EOS])
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Jun 2021
- Study start22 Jul 2021
- Primary completion16 Apr 2024
- Study completion16 Apr 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for SchizophreniaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Enrolment
- 93 participants (actual)
Sponsor and investigators
- Lead sponsor
- Janssen-Cilag International NV
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Janssen-Cilag International NV Clinical Trial, Study director, Janssen-Cilag International NV
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04940039
- Sponsor's protocol ID
- CR108924
- Other IDs
- R092670PSY4002
- Acronym
- CASPAR
- Status last verified
- Apr 2025
- First submitted
- 22 Jun 2021
- Last updated
- 27 Apr 2025
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Publications
Bizoza R, Mehawej J, Musoni-Rwililiza E, Alphs L, Turkoz I, Sun L, Killion L, Decotelli-Mendes C, Knight RK. Efficacy and safety of long-acting injectable paliperidone palmitate 1-month and 3-month formulations in the maintenance treatment of schizophrenia: a single-arm, open-label, interventional study in Rwandan healthcare settings. BMJ Open. 2026 Jun 16;16(6):e109753. doi: 10.1136/bmjopen-2025-109753.
PubMed 42303401
Study at a glance
From the registry record, last updated by the sponsor on 27 Apr 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Clinical Study to Assess the Treatment of Schizophrenia With Paliperidone Palmitate in Rwandan Healthcare Settings
- ClinicalTrials.gov ID
- NCT04940039
- Acronym / sponsor ID
- CASPAR / CR108924
- Conditions
- Schizophrenia
- Keywords
- Long-acting injectable antipsychotics, Low income countries, schizophrenia
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 93 participants (actual)
- Lead sponsor
- Janssen-Cilag International NVIndustry (pharma, biotech, devices)
- Study start
- 22 Jul 2021 (actual)
- Primary completion
- 16 Apr 2024 (actual)
- Study completion
- 16 Apr 2024 (actual)
- First posted
- 25 Jun 2021 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the long-term symptomatic response (Visit 2 [Week 1] to Visit 14/Week 66 [End of Study {EOS}]) measured by change in the Clinical Global Impressions -Severity for Schizophrenia (CGI-SS) in participants with schizophrenia who are treated in Rwandan real-world healthcare settings with the antipsychotic regimen that starts with oral anti-psychotic (AP) formulation followed by continued treatment with (paliperidone palmitate 1-month [PP1M] and 3-month [PP3M] formulations).
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
| Arm | Type | Receives |
|---|---|---|
| Paliperidone Palmitate | Experimental | Drug: Risperidone 3 mg, Drug: Paliperidone Palmitate 50 mg eq., Drug: Paliperidone Palmitate 75 mg eq., Drug: Paliperidone Palmitate 100 mg eq., Drug: Paliperidone Palmitate 150 mg eq., Drug: Paliperidone Palmitate 175 mg eq., Drug: Paliperidone Palmitate 263 mg eq., Drug: Paliperidone Palmitate 350 mg eq., Drug: Paliperidone Palmitate 525 mg eq.Participants in Observation Phase will receive their treatment prescribed by treating physicians as part of their routine clinical practice and the standard of care (SoC) treatment for Rwanda mental healthcare settings. Participants who have not received risperidone or paliperidone or paliperidone palmitate earlier in Observation Phase will receive oral risperidone 3 milligram (mg) tablets once daily for 3 days in Run-in Phase to determine tolerability. Participants will receive flexible dose range from 50 to 150 mg equivalent (eq.) long acting formulation of paliperidone palmitate once monthly (PP1M) as an intramuscular (IM) injection in Lead-in Treatment Phase for at least 17 weeks (maximum 25 weeks) and if stable dose is achieved for PP1M, participants will enter Maintenance Treatment Phase and continue to receive flexible dose range from 175 to 525 mg eq. long acting formulation of paliperidone palmitate every 3 months (PP3M) as an IM injection for up to 24 weeks. |
Who may qualify
- Ages
- 19 to 34 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Diagnosis of schizophrenia by Mini International Neuropsychiatric Interview (MINI)-Screen / MINI (Module K) that requires treatment initiation or a change in treatment to better address safety, efficacy, or adherence limitations of current treatment
- Eligible for treatment in the Rwandan mental healthcare system
- At least moderately ill as measured by the Clinical Global Impression - Severity of Schizophrenia (CGI-SS) scale for schizophrenia (rating of greater than or equal to [>=] 4). This criterion needs to be re-confirmed at Visit 2
- Has a primary caregiver who is willing to participate in this study (caregiver should be knowledgeable about the participant's condition, provide economic/cost of care information, and is expected to be with the participant for greater than [>] 24 hours each week for the duration of the study)
- A woman of childbearing potential must have a negative highly sensitive serum (beta-human chorionic gonadotropin [beta-hCG]) during screening
Key exclusion criteria (6 listed)
- Has a physical, mental, or legal incapacity that prevents a valid consent or capacity to complete about 12 months of treatment with antipsychotic medication and compliance with this study protocol
- History of organic brain syndromes, comorbid psychiatric and/or physical illnesses, or significant comorbid substance abuse that is likely to interfere with understanding of or compliance with study requirements
- Known allergies, hypersensitivity, or intolerance to risperidone or paliperidone palmitate or its excipients
- Received an investigational intervention including investigational vaccines or used an invasive investigational medical device within 30 days before the planned first dose of study intervention, or is currently enrolled in an investigational study
- Pregnant, or breast-feeding, or planning to become pregnant while enrolled in this study or within 6 months after the last dose of study intervention
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Risperidone 3 mgParticipants will receive 3 mg oral risperidone tablet once daily for 3 days. | Drug | Paliperidone Palmitate |
| Paliperidone Palmitate 50 mg eq.Also: R092670Participants will receive 50 mg eq. PP1M IM injection for at least 17 weeks (maximum 25 weeks). | Drug | Paliperidone Palmitate |
| Paliperidone Palmitate 75 mg eq.Also: R092670Participants will receive 75 mg eq. PP1M IM injection for at least 17 weeks. | Drug | Paliperidone Palmitate |
| Paliperidone Palmitate 100 mg eq.Also: R092670Participants will receive 100 mg eq. PP1M IM injection for at least 17 weeks. | Drug | Paliperidone Palmitate |
| Paliperidone Palmitate 150 mg eq.Also: R092670Participants will receive 150 mg eq. PP1M IM injection for at least 17 weeks. | Drug | Paliperidone Palmitate |
| Paliperidone Palmitate 175 mg eq.Also: R092670Participants will receive 175 mg eq. PP3M IM injection up to 24 weeks. | Drug | Paliperidone Palmitate |
| Paliperidone Palmitate 263 mg eq.Also: R092670Participants will receive 263 mg eq. PP3M IM injection up to 24 weeks. | Drug | Paliperidone Palmitate |
| Paliperidone Palmitate 350 mg eq.Also: R092670Participants will receive 350 mg eq. PP3M IM injection up to 24 weeks. | Drug | Paliperidone Palmitate |
| Paliperidone Palmitate 525 mg eq.Also: R092670Participants will receive 525 mg eq. PP3M IM injection up to 24 weeks. | Drug | Paliperidone Palmitate |
Primary outcome
Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}])
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
The CGI-SS will be used to provide a clinical measure of the severity of schizophrenia. It is a single-item Likert scale with a 7-point range (1 indicates none to 7 indicates extreme symptoms).
21 secondary outcomes
Mean Change in CGI-SS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Mean Change in CGI-SS Score from Visit 2 (Week 1) to Visit 6 (Week 25)
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Personal and Social Performance (PSP) Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in PSP Scale Scores from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in PSP Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in Patient Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in Patient Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in Clinician Satisfaction Rating Scale Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in Clinician Satisfaction Rating Scale Score from Visit 2 (Week 1) to Visit 6 (Week 25)
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Change in Schizophrenia Quality of Life Scale (SQLS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])
Change in SQLS Score from Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Time frame: Visit 6 (Week 25) to Visit 14 (Week 66 [EOS])
Change in SQLS Score from Visit 2 (Week 1) to Visit 6 (Week 25)
Time frame: Visit 2 (Week 1) to Visit 6 (Week 25)
Number of Participants with Treatment-emergent Adverse Events
Time frame: Up to Week 66
Number of Participants with Abnormalities in Clinical Laboratory Measures
Time frame: Up to Week 66
Number of Participants with Abnormalities in Vital Signs
Time frame: Up to Week 66
Number of Participants with Abnormalities in Electrocardiogram (ECG)
Time frame: Up to Week 66
Number of Participants with Abnormalities in Physical Examination
Time frame: Up to Week 66
Number of Participants With Pregnancy Outcome as a Safety Measure
Time frame: Up to Week 66
Number of Participants With Suicidal Ideation and Behavior as Assessed by Columbia Suicide Severity Rating Scale (C-SSRS) Score
Time frame: Visit 12 (Week 46) to Visit 14 (Week 66 [EOS])
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Apr 2025.
- Derived from this study: PubMed 42303401Bizoza R, Mehawej J, Musoni-Rwililiza E, Alphs L, Turkoz I, Sun L, Killion L, Decotelli-Mendes C, Knight RK. Efficacy and safety of long-acting injectable paliperidone palmitate 1-month and 3-month formulations in the maintenance treatment of schizophrenia: a single-arm, open-label, interventional study in Rwandan healthcare settings. BMJ Open. 2026 Jun 16;16(6):e109753. doi: 10.1136/bmjopen-2025-109753.
- Individual participant dataSharing planned: Yes. The data sharing policy of the Janssen Pharmaceutical Companies of Johnson \& Johnson is available at www.janssen.com/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Related trials for Schizophrenia
RecruitingPhase 3
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
Schizophrenia, Autism-Related Irritability
Not yet recruiting
Deep Brain Stimulation for Treatment-Resistant Schizophrenia
Treatment Resistant Disorders
Not yet recruitingObservational study
Sleep Monitoring for Early Detection of Relapse in People With Schizophrenia or Bipolar Disorder Receiving Usual Treatment
Bipolar Disorder (BD), SCHIZOPHRENIA 1 (Disorder)
Not yet recruitingPhase 1
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
Healthy Adult Participants
Active, not recruiting
Designing and Evaluating a Classroom-Based Mental Health Programme for Adolescents.
Mental Health Promotion
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Janssen-Cilag International NV Clinical Trial study director
Janssen-Cilag International NV
5 sites in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing Risperidone 3 mg, Paliperidone Palmitate 50 mg eq. and Paliperidone Palmitate 75 mg eq. in people with Schizophrenia, run by Janssen-Cilag International NV at 5 sites in Rwanda.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 27 Apr 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 5 sites in Rwanda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Mean Change in Clinical Global Impression Severity of Schizophrenia (CGI-SS) Score from Visit 2 (Week 1) to Visit 14 (Week 66 [End of Study {EOS}]) (time frame: Visit 2 (Week 1) to Visit 14 (Week 66 [EOS])). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04940039, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Apr 2025.